• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    3/11/24 1:41:28 PM ET
    $ATXI
    $BALY
    $BIAF
    $BILI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Hotels/Resorts
    Consumer Discretionary
    Get the next $ATXI alert in real time by email

    Shares of Mesoblast Limited (NASDAQ:MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients.

    Mesoblast shares jumped 13.4% to $2.4399 on Monday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Kidpik Corp. (NASDAQ:PIK) gained 238% to $9.15. Kidpik recently announced a 1-for 5 reverse stock split.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares surged 149% to $2.6450.
    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) gained 114.6% to $17.26. TRxADE Health recently announced a special cash dividend of $8 per share.
    • Fangdd Network Group Ltd. (NASDAQ:DUO) shares climbed 108% to $1.2593 after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector.
    • GDS Holdings Limited (NASDAQ:GDS) shares gained 23.7% to $7.93 following a report suggesting Hillhouse and Boyu are in talks to invest in the company's Southeast Asia data center business.
    • Solidion Technology Inc. (NASDAQ:STI) rose 23.3% to $0.9620.
    • Kingsoft Cloud Holdings Limited (NASDAQ:KC) shares gained 23.1% to $3.31. Kingsoft Cloud is expected to report fourth-quarter financial results on March 20, 2024.
    • EHang Holdings Limited (NASDAQ:EH) gained 21.7% to $13.89. EHang Holdings is expected to release its unaudited financial results for the fourth quarter on March 15, 2024.
    • Bally's Corporation (NYSE:BALY) gained 21.5% to $12.90. Standard General delivered a non-binding letter to the board of directors of Bally's proposing a transaction under which it would acquire all of the outstanding shares of common stock for $15/share, not currently owned by the company.
    • Rail Vision Ltd. (NASDAQ:RVSN) climbed 21.2% to $3.43. Rail Vision received an order from a Class 1 US railroad company for its AI-based safety system.
    • Marpai, Inc. (NASDAQ:MRAI) gained 18.7% to $2.0899.
    • bioAffinity Technologies, Inc. (NASDAQ:BIAF) climbed 18.3% to $1.81.
    • Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) gained 15.6% to $4.8797.
    • Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) jumped 13.4% to $2.4650 after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.
    • NWTN Inc. (NASDAQ:NWTN) gained 13.4% to $4.8082.
    • Pulse Biosciences, Inc. (NASDAQ:PLSE) rose 12.7% to $10.86. Pulse Biosciences announced FDA 510(k) clearance for Cellfx NSPFA Percutaneous Electrode System.
    • Bilibili Inc. (NASDAQ:BILI) gained 12.7% to $12.55 after JP Morgan upgraded the stock from Underweight to Neutral and raised its price target from $10 to $11. The stock is also gaining amid overall China strength following the annual National People's Congress event.
    • Graphite Bio, Inc. (NASDAQ:GRPH) climbed 11.7% to $3.5080. Graphite Bio declared a special dividend in connection with proposed merger with Lenz Therapeutics.
    • STAAR Surgical Company (NASDAQ:STAA) jumped 10% to $39.45 after Stifel upgraded the stock from Hold to Buy and raised its price target from $30 to $50.
    • VNET Group, Inc. (NASDAQ:VNET) rose 9.8% to $1.68.
    • Moderna, Inc. (NASDAQ:MRNA) gained 9.2% to $112.51.
    • Ituran Location and Control Ltd. (NASDAQ:ITRN) climbed 7.8% to $28.42.
    • NuScale Power Corporation(NYSE:SMR) gained 7% to $5.87. NuScale Power is expected to release fourth quarter results on March 14, 2024.
    • MicroStrategy Incorporated (NASDAQ:MSTR) gained 4.7% to $1,492.07 amid continued strength in Bitcoin.

    Losers

    • Jeffs' Brands Ltd (NASDAQ:JFBR) fell 45.2% to $0.8650.
    • Eltek Ltd. (NASDAQ:ELTK) shares fell 20.9% to $11.00 after the company announced downbeat quarterly earnings.
    • CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) declined 22% to $3.0822 after jumping 28% on Friday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients.
    • The Real Good Food Company, Inc. (NASDAQ:RGF) fell 19.7% to $0.5536.
    • Ventyx Biosciences, Inc. (NASDAQ:VTYX) dipped 18.5% to $8.09. Ventyx Biosciences reported clinical data for its NLRP3 inhibitor portfolio and issued pipeline updates at Virtual Investor Event.
    • Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) fell 15.3% to $6.78 after declining 8% on Friday. Lytus Technologies, last week, announced the launch of Lytus Cloud.
    • Next.e.GO N.V. (NASDAQ:EGOX) declined 15.3% to $0.0727.
    • MoneyLion Inc. (NYSE:ML) fell 15% to $63.36.
    • Semilux International Ltd. (NASDAQ:SELX) fell 14.8% to $1.4403 after jumping 69% on Friday.
    • Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) fell 14.6% to $6.83.
    • Barnes & Noble Education, Inc. (NYSE:BNED) dipped 13.8% to $0.7832. Barnes & Noble Education recently rescheduled its third quarter fiscal year 2024 earnings release.
    • Psyence Biomedical Ltd. (NASDAQ:PBM) fell 13.4% to $1.8272 after jumping 66% on Friday. The company recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study.
    • Immuron Limited (NASDAQ:IMRN) shares tumbled 12.5% to $3.3252 after dipping 16% on Friday.
    • Genie Energy Ltd. (NYSE:GNE) fell 12% to $16.67 following fourth-quarter results.
    • Nanobiotix S.A. (NASDAQ:NBTX) dipped 9.8% to $6.35.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) fell 8.9% to $0.1749 after surging 10% on Friday.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) dipped 8.8% to $1,039.60.
    • MannKind Corporation (NASDAQ:MNKD) declined 8.7% to $4.81. MannKind announced initial meal challenge data from INHALE-3 Phase 4 U.S. trial comparing afrezza head-to-head with multiple daily injections and insulin pumps.
    • Poseida Therapeutics, Inc. (NASDAQ:PSTX) fell 8.1% to $3.74.

     

    Now Read This: Wall Street's Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 3% Dividend Yields

    Get the next $ATXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXI
    $BALY
    $BIAF
    $BILI

    CompanyDatePrice TargetRatingAnalyst
    Bilibili Inc.
    $BILI
    3/27/2026$27.00Neutral → Buy
    Citigroup
    Super Micro Computer Inc.
    $SMCI
    3/23/2026$22.00Outperform → Market Perform
    Northland Capital
    Super Micro Computer Inc.
    $SMCI
    3/20/2026Buy → Hold
    Argus
    Super Micro Computer Inc.
    $SMCI
    3/20/2026Market Perform → Market Underperform
    CJS Securities
    Bilibili Inc.
    $BILI
    3/17/2026$35.00Neutral → Overweight
    Analyst
    Ituran Location and Control Ltd.
    $ITRN
    3/12/2026$70.00Buy
    Maxim Group
    Strategy Inc
    $MSTR
    3/10/2026$175.00Buy
    B. Riley Securities
    MannKind Corporation
    $MNKD
    2/27/2026$3.50Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $ATXI
    $BALY
    $BIAF
    $BILI
    SEC Filings

    View All

    Pulse Biosciences Inc filed SEC Form 8-K: Leadership Update

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    3/27/26 4:32:55 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by STAAR Surgical Company

    SCHEDULE 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    3/27/26 1:17:37 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Super Micro Computer Inc.

    SCHEDULE 13G/A - Super Micro Computer, Inc. (0001375365) (Subject)

    3/27/26 1:16:40 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ATXI
    $BALY
    $BIAF
    $BILI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bilibili upgraded by Citigroup with a new price target

    Citigroup upgraded Bilibili from Neutral to Buy and set a new price target of $27.00

    3/27/26 9:03:14 AM ET
    $BILI
    EDP Services
    Technology

    Super Micro Computer downgraded by Northland Capital with a new price target

    Northland Capital downgraded Super Micro Computer from Outperform to Market Perform and set a new price target of $22.00

    3/23/26 8:27:58 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    Super Micro Computer downgraded by Argus

    Argus downgraded Super Micro Computer from Buy to Hold

    3/20/26 3:05:11 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ATXI
    $BALY
    $BIAF
    $BILI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tonnel David A

    4 - NUSCALE POWER Corp (0001822966) (Issuer)

    3/26/26 4:02:07 PM ET
    $SMR
    Metal Fabrications
    Industrials

    SEC Form 3 filed by new insider Qu Heng

    3 - Kingsoft Cloud Holdings Ltd (0001795589) (Issuer)

    3/26/26 9:07:45 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by new insider Sheratzky Efraim

    3 - Ituran Location & Control Ltd. (0001337117) (Issuer)

    3/26/26 8:54:31 AM ET
    $ITRN
    Electronic Components
    Technology

    $ATXI
    $BALY
    $BIAF
    $BILI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/13/26 7:59:59 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Chief Executive Officer Castagna Michael bought $259,000 worth of shares (100,000 units at $2.59), increasing direct ownership by 4% to 2,575,911 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    3/10/26 9:30:02 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BALY
    $BIAF
    $BILI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATXI
    $BALY
    $BIAF
    $BILI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jeffs' Brands: KeepZone AI Enters into Agent Agreement with Skyline Software Systems to Offer 3D Geospatial Visualization Solutions to Global Security Markets

    Tel Aviv, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd ("Jeffs' Brands" or the "Company") (NASDAQ:JFBR, JFBRW)), a data-driven e-commerce company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence ("AI") – driven solutions, today announced that its wholly-owned subsidiary, KeepZone AI Inc. ("KeepZone"), has entered into a non-exclusive Agent Agreement (the "Agreement") with Skyline Software Systems, Inc. ("Skyline"), a  leading provider of 3D geospatial visualization software and services. Under the terms of the Agreement, KeepZone is authorized to market, sell, and distribute Skyline's proprieta

    3/27/26 8:55:00 AM ET
    $JFBR
    Other Specialty Stores
    Consumer Discretionary

    NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

    PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office

    3/26/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eltek Announces Filing of 2025 Annual Report

    PETACH-TIKVA, Israel, March 26, 2026 /PRNewswire/ -- Eltek Ltd. (NASDAQ:ELTK), a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards, announced today that it filed its annual report, containing audited consolidated financial statements for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The annual report is available on the Company's website at www.nisteceltek.com. Shareholders may receive a hard copy of the annual report free of charge upon request.About EltekEltek – "Innovation Across the Board", is a global manufacturer and supplier of technologically advanced solutions in the field of printed ci

    3/26/26 4:10:00 PM ET
    $ELTK
    Electrical Products
    Technology

    $ATXI
    $BALY
    $BIAF
    $BILI
    Leadership Updates

    Live Leadership Updates

    View All

    Super Micro Computer Announces Resignation of Board Member Yih-Shyan "Wally" Liaw

    DeAnna Luna Appointed Acting Chief Compliance OfficerSAN JOSE, Calif., March 20, 2026 /PRNewswire/ -- Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company") today announced that Yih-Shyan "Wally" Liaw ("Mr. Liaw") has resigned from the Company's Board of Directors, effective immediately. Following Mr. Liaw's resignation, the Company's Board comprises eight directors. There are no changes to the Board's committee structure. The Company also announced today that it has appointed DeAnna Luna as acting Chief Compliance Officer, effective immediately. Ms. Luna brings to this role more than two decades of experience in global trade compliance, governance, highly regulated markets

    3/20/26 4:38:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BALY
    $BIAF
    $BILI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATXI
    $BALY
    $BIAF
    $BILI
    Financials

    Live finance-specific insights

    View All

    NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

    PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office

    3/26/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kingsoft Cloud Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

    BEIJING, March 25, 2026 /PRNewswire/ -- Kingsoft Cloud Holdings Limited ("Kingsoft Cloud" or the "Company") (NASDAQ:KC), a leading cloud service provider in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Mr. Tao Zou, Chief Executive Officer of Kingsoft Cloud, commented, "We are very pleased to see another strong quarter to close the fiscal year of 2025. Our record-high financial result is a powerful testament to the confidence our customers place in our products, solutions and services. This quarter our gross billing of AI business achieved a year-over-year growth of 95%, and we continue to see strong intelligent computi

    3/25/26 7:57:00 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    Genie Energy Announces Select, Preliminary, Unaudited, Interim Financial Results

    Newark, NJ, March 19, 2026 (GLOBE NEWSWIRE) -- Genie Energy, Ltd. (NYSE:GNE), a leading retail energy and renewable energy solutions provider, today provided an update on its fourth quarter and full year 2025, including select unaudited, preliminary financial results, as well as financial guidance for 2026. As disclosed on the 8-K filed on March 12, 2026, the Audit Committee of the Company's Board of Directors, in consultation with the Company's management and independent registered public accounting firm, has concluded that the Company's previously issued financial statements for the years ended December 31, 2024 and December 31, 2023 as well as the interim quarterly reports for 2024 and

    3/19/26 4:30:00 PM ET
    $GNE
    Power Generation
    Utilities